Login / Signup

MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS -Mutated Non-Small Cell Lung Cancer.

Francesca FaniniErika BandiniMeropi PlousiouSilvia CarloniPetra WisePaolo NevianiMariam MurtadhaFlavia FocaFrancesco FabbriIvan VanniniMuller Fabbri
Published in: International journal of molecular sciences (2021)
-activating mutations.
Keyphrases
  • wild type
  • signaling pathway
  • pi k akt
  • chronic myeloid leukemia
  • cell proliferation